Största ägaren Symrise lägger ett bud om 350 kronor per aktie i syfte att förvärva hela bolaget.
Redeye comments on Ngenic’s announcement of a SEK34m rights issue of units consisting of shares and ...
Redeye comments on the outcome of Iconovo’s rights issue.
Luxbright (”Luxbright” eller ”Bolaget”) fortsätter att uppvisa starkt momentum med flera framgångar ...
Medical cannabis has been legal in Denmark under a pilot program since 2018 during a trial period th...
Redeye comments on Flexion Mobile's Q3 2024 report, which was better than expected in terms of margi...
Q3 EBIT -94m (ABGSCe SEK -19m) Minor estimate revisions, given Q3 small quarter Fågelås, Boarp, Dåll...
Redeye comments on Alligator's sale of two bispecific antibodies to Orion, which were being develope...
Redeye updates its fair value range following Friday’s Q3 report and after the outcome of the extra ...
Redeye comments on Lytix' Q3 report. The main event since our last update is the start of the NeoLIP...
FY'24 ARR guidance lowered to DKK 101m-106m on KYC delays.
Redeye provides a research update following the Q3 report recently published by Coegin Pharma.
Den 6:e november kommenterade Analysguiden iZafes rapport för det tredje kvartalet.
Following the end of Q3-24, Pharma Equity Group (“PEG” or “the Company”) secured additional funding ...
Redeye comments on Active Biotech's 2024 rights issue and updates its base case.
Refine Group AB (”Refine”, ”Koncernen” eller ”Bolaget”) är en varumärkesgrupp med ett digitalt fokus...
Underliggande verksamheter går fortsatt mycket bra, men viss mixförskjutning och förberedelsekostnad...
Redeye comments on Embracer's announcment of Asmodee's financial targets and an equity investment of...
Redeye downgrades Nekkar’s outlook on the back of a Q3’24 report that missed our forecast, mainly dr...
Lumi Gruppen continues to see high demand for its ONH courses, reporting a 20% y/y revenue increase ...
